博想醫學科技是 2020 年從國立台灣大學蕭浩明教授實驗室衍生的新創公司。蕭教授的使命是要研發革命性的創新技術並協助未來的醫療產業,並將技術轉為商品應用於臨床醫學。

我們的首個產品——PulStroke——是一種創新的快篩設備用於檢測頸動脈狹窄,並作為腦中風的早期黃金指標。

PulStroke 是一種非侵入式、非放射性且極易操作的檢測工具。使用 PulStoke 進行的檢測流程非常簡便,只需針對受測者的脖子區域進行20秒的影像錄製,我們的雲端演算系統就會立即進行分析,並將檢測結果於五分鐘內提供給使用者,只需使用自身的智慧型手機就可以觀看報告。

未來我們預計持續使用我們的演算核心,開發不同的疾病應用,包含洗腎動靜脈廔管阻塞及帕金森氏症等。

PulStroke 預計將於 2022 年中取得 TFDA 許可證。

Pulxion was span off from Professor Hao-Ming Hsiao’s lab at National Taiwan University in 2020. Professor Hsiao’s mission is to develop novel technologies to help reshape the future medical industry, with the goals of translating his research work into clinical solutions and commercial products.

Our first project “PulStroke” is a novel fast-screening medical device aiming to screen for carotid artery stenosis, an early indicator of stroke.

The device is a non-invasive, non-radioactive and easy-to-operate assessment tool. With PulStroke, screening results can be accessed by users via the device or users' smartphones within 5 minutes: the device first records a 20-second clip of the user’s anterior neck skin under LED light, our cloud algorithm then analyzes such data and delivers results to the users.

In the near future, we will expand our algorithm application to include arteriovenous fistula stenosis.

PulStroke is expected to receive TFDA approval by 2022.